N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up
- 29 September 2004
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 148 (4) , 690-695
- https://doi.org/10.1016/j.ahj.2004.05.015
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Prophylaxis of contrast‐induced nephropathy in patients undergoing coronary angiographyCatheterization and Cardiovascular Interventions, 2003
- A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID studyJournal of the American College of Cardiology, 2003
- Acetylcysteine for Prevention of Acute Deterioration of Renal Function Following Elective Coronary Angiography and InterventionJAMA, 2003
- A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiographyKidney International, 2002
- Prospective randomized study of N‐acetylcysteine, fenoldopam, and saline for prevention of radiocontrast‐induced nephropathyCatheterization and Cardiovascular Interventions, 2002
- Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedureJournal of the American College of Cardiology, 2002
- Acetylcysteine and contrast agent-associated nephrotoxicityJournal of the American College of Cardiology, 2002
- Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial)The American Journal of Cardiology, 2002
- The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiencyJournal of the American College of Cardiology, 2000
- Prevention of Radiographic-Contrast-Agent–Induced Reductions in Renal Function by AcetylcysteineNew England Journal of Medicine, 2000